Patents by Inventor Jingye Zhou

Jingye Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS
    Publication number: 20180296560
    Abstract: The present invention provides compounds of the formula below pharmaceutically acceptable salts of the compounds, methods of treating patients for liver disease, and processes for preparing the compounds.
    Type: Application
    Filed: June 19, 2018
    Publication date: October 18, 2018
    Inventors: Mengyang Fan, Luoheng Qin, Yi Wei, Guoqiang Zhou, Jingye Zhou
  • AMINO PYRIMIDINE SSAO INHIBITORS
    Publication number: 20180297987
    Abstract: The present invention provides compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, where n and R1 are defined herein, methods of treating patients for liver disease, and processes for preparing the compounds.
    Type: Application
    Filed: June 19, 2018
    Publication date: October 18, 2018
    Inventors: David Andrew Coates, Luo Heng Qin, Yi Wei, Jingye Zhou
  • Tetrahydropyranyl Benzamide Derivatives
    Publication number: 20180194755
    Abstract: The present invention provides compounds of the Formula below wherein R, R1-R3 are as described herein; methods of treating patients for diabetes using the compounds, and processes for preparing the compounds
    Type: Application
    Filed: February 19, 2016
    Publication date: July 12, 2018
    Inventors: Zhi Long Hu, Lian Zhu Liu, Tianwei Ma, Haizhen Zhang, Jingye Zhou
  • GPR142 agonist compounds
    Patent number: 9861613
    Abstract: The present invention provides compounds of the Formula (Ia) wherein R is selected from the group consisting of CH3, CH(CH3)2, CH2CN, CH2CHF2, CH2CF3, (A), (B), (C), (D), (E), (F), CH2CH2OCH3, and CH2C(O)OCH(CH3)2; R1 is selected from the group consisting of CF3, OCF3, and Cl; R2 is selected from the group consisting of H and F; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: January 9, 2018
    Assignee: Eli Lilly and Company
    Inventors: Zhi Long Hu, Lian Zhu Liu, Tianwei Ma, Mi Emily Zeng, Jingye Zhou
  • TETRACYCLINE COMPOUNDS
    Publication number: 20170334841
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.
    Type: Application
    Filed: March 1, 2017
    Publication date: November 23, 2017
    Inventors: Yonghong Deng, Louis Plamondon, Cuixiang Sun, Xiao-Yi Xiao, Jingye Zhou, Joyce A. Sutcliffe, Magnus P. Ronn
  • PYRAZOLE COMPOUNDS
    Publication number: 20170334885
    Abstract: This invention relates to pyrazole compounds or pharmaceutically acceptable salts thereof. Compounds of this invention are inhibitors of methionine aminopeptidase 2 (MetAP2) and dipeptidyl peptidase-4 (DPP-4). MetAP2 is a metalloproteinase that cleaves initiator methionine from nascent peptide emerging from the ribosomes. WO 2010/065879 reports small molecule MetAP2 inhibitors for obesity treatment. DPP-4 inhibitors are an established drug class to improve glycemic control in patients with type 2 diabetes mellitus. Compounds with dual inhibitory activity in both MetAP2 and DPP-4 are desired. The present invention provides novel compounds with dual MetAP2 and DPP-4 inhibitition. These dual inhibitor compounds can be useful in the treatment of a MetAP2 and DPP-4 mediated condition. The present invention provides a compound of the following Formula (I); or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 11, 2016
    Publication date: November 23, 2017
    Inventors: Koc Kan Ho, Weiqiang Zhan, Jingye Zhou
  • Pyrazole compounds
    Patent number: 9822101
    Abstract: This invention relates to pyrazole compounds or pharmaceutically acceptable salts thereof. Compounds of this invention are inhibitors of methionine aminopeptidase 2 (MetAP2) and dipeptidyl peptidase-4 (DPP-4). MetAP2 is a metalloproteinase that cleaves initiator methionine from nascent peptide emerging from the ribosomes. WO 2010/065879 reports small molecule MetAP2 inhibitors for obesity treatment. DPP-4 inhibitors are an established drug class to improve glycemic control in patients with type 2 diabetes mellitus. Compounds with dual inhibitory activity in both MetAP2 and DPP-4 are desired. The present invention provides novel compounds with dual MetAP2 and DPP-4 inhibitition. These dual inhibitor compounds can be useful in the treatment of a MetAP2 and DPP-4 mediated condition. The present invention provides a compound of the following Formula (I); or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: November 21, 2017
    Assignee: Eli Lilly and Company
    Inventors: Koc Kan Ho, Weiqiang Zhan, Jingye Zhou
  • C7-Fluoro Substituted Tetracycline Compounds
    Publication number: 20170275244
    Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
    Type: Application
    Filed: November 9, 2016
    Publication date: September 28, 2017
    Inventors: Jingye Zhou, Xiao-Yi Xiao, Louis Plamondon, Diana Katharine Hunt, Roger B. Clark, Robert Zahler
  • GPR142 Agonist Compounds
    Publication number: 20170165234
    Abstract: The present invention provides compounds of the Formula (Ia) wherein R is selected from the group consisting of CH3, CH(CH3)2, CH2CN, CH2CHF2, CH2CF3, (A), (B), (C), (D), (E), (F), CH2CH2OCH3, and CH2C(O)OCH(CH3)2; R1 is selected from the group consisting of CF3, OCF3, and Cl; R2 is selected from the group consisting of H and F; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 22, 2015
    Publication date: June 15, 2017
    Inventors: Zhi Long Hu, Lian Zhu Liu, Tianwei Ma, Mi Emily Zeng, Jingye Zhou
  • Tetracycline compounds
    Patent number: 9624166
    Abstract: The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: April 18, 2017
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Yonghong Deng, Louis Plamondon, Cuixiang Sun, Xiao-Yi Xiao, Jingye Zhou, Joyce A. Sutcliffe, Magnus P. Ronn
  • C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS
    Publication number: 20150274643
    Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
    Type: Application
    Filed: November 4, 2014
    Publication date: October 1, 2015
    Inventors: Jingye Zhou, Xiao-Yi Xiao, Louis Plamondon, Diana Katharine Hunt, Roger B. Clark, Robert Zahler
  • C7-fluoro substituted tetracycline compounds
    Patent number: 8906887
    Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: December 9, 2014
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Jingye Zhou, Xiao-Yi Xiao, Louis Plamondon, Diana Katharine Hunt, Roger B. Clark, Robert B. Zahler
  • C7-fluoro substituted tetracycline compounds
    Patent number: 8796245
    Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: August 5, 2014
    Assignee: TetraPhase Pharmaceuticals, Inc.
    Inventors: Jingye Zhou, Xiao-Yi Xiao, Louis Plamondon, Diana Katharine Hunt, Roger B. Clark, Robert B. Zahler
  • C7-fluoro substituted tetracycline compounds
    Patent number: 8501716
    Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: August 6, 2013
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Jingye Zhou, Xiao-Yi Xiao, Louis Plamondon, Diana Katharine Hunt, Roger B. Clark, Robert B. Zahler
  • C7-Fluoro Substituted Tetracycline Compounds
    Publication number: 20130109657
    Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
    Type: Application
    Filed: December 18, 2012
    Publication date: May 2, 2013
    Applicant: Tetraphase Pharmaceuticals, Inc.
    Inventors: Jingye Zhou, Xiao-Yi Xiao, Louis Plamondon, Diana Katharine Hunt, Roger B. Clark, Robert B. Zahler
  • C7-Fluoro Substituted Tetracycline Compounds
    Publication number: 20120302527
    Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
    Type: Application
    Filed: August 9, 2012
    Publication date: November 29, 2012
    Applicant: Tetraphase Pharmaceuticals, Inc.
    Inventors: Jingye Zhou, Xiao-Yi Xiao, Louis Plamondon, Diana Katharine Hunt, Roger B. Clark, Robert B. Zahler
  • Tetracycline Compounds
    Publication number: 20120208788
    Abstract: The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.
    Type: Application
    Filed: August 27, 2010
    Publication date: August 16, 2012
    Inventors: Yonghong Deng, Louis Plamondon, Cuixiang Sun, Xiao-Yi Xiao, Jingye Zhou, Joyce A. Sutcliffe, Magnus P. Ronn
  • C7-fluoro substituted tetracycline compounds
    Publication number: 20100105671
    Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
    Type: Application
    Filed: August 7, 2009
    Publication date: April 29, 2010
    Inventors: Jingye Zhou, Xiao-Yi Xiao, Louis Plamondon, Diana Katharine Hunt, Roger B. Clark, Robert B. Zahler